ClinicalTrials.gg
RecruitingNCT04855435Updated Aug 10, 2026

Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

A Phase 1 interventional study of MBS8(1V270) and MBS8(1V270) and pembrolizumab combination in Advanced Solid Tumor, Uveal Melanoma, Metastatic and Cutaneous Melanoma, sponsored by MonTa Biosciences ApS. Recruiting at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by MonTa Biosciences ApS · Phase 1, Interventional, and Treatment

How we know · 6 judgments

From the registry’s dates

  • Started Apr 2021; still recruiting 5 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
106
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Uveal Melanoma with a site in Spain — 4 open to participants now, 11 under way, 4 of them phase 3. Uveal Melanoma · Spain.

Planned enrollment
10th of 22
106 · median 94
Started
2021
with 3 others
Phase 1
4 of 22
1 open now
Primary completion
2027-03
later than 5 of 10 live
Registered
12th of 22
by date

Among the 22 studies in Uveal Melanoma with a site in Spain, this one is the 10th largest by planned enrollment, is one of 4 that started in 2021, is one of 4 in phase 1, reaches primary completion later than 5 of the 10 other live ones, and was the 12th registered.

Uveal Melanoma

281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.

Browse Uveal Melanoma studies →

Open to participants now

4 of the 22 studies in Uveal Melanoma with a site in Spain are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 43 Uveal Melanoma studies recruiting now, 36 (84%) set no upper age limit and 4 (9%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Uveal Melanoma with a site in Spain, or all of them as a file.
02

Study summary

The Phase I trial is evaluating safety, tolerability, pharmacokinetics and preliminary efficacy of MBS8(1V270) in subjects with advanced solid tumours. The trial is designed to provide data for further clinical development of MBS8(1V270)

Read the detailed description

This is a prospective, open-label, two arms, multinational, multicenter Phase I trial in subjects with advanced solid tumors.

The trial consists of two stages: Stage I is a dose escalation stage which will include up to eight cohorts with escalating doses of MBS8(1V270) to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D). Stage II is an expansion phase in which safety and tolerability of MBS8(1V270) will be assessed at the recommended phase 2 dose established in Stage I of the trial. Stage II comprices two cohorts: One cohort in which MBS8(1V270) will be evaluated in combination with pembrolizumab (Keytruda) in cutaneous melanoma patients with acquired resistance to PD-1 therapy; and one cohort in which MBS8(1V270) will be evaluated as monotherapy in uveal melanoma patients previously treated with T-cell engagers.

The dose-escalation in stage 1 is based on the 1+2 design for the first cohort and on the 3+3 design for the following cohorts.

The investigational medicinal product is a TLR7 agonist and will be administered intravenously by infusion.

Subjects will be treated in cycles. Plasma cytokine levels will be assessed, and tumor biopsies will be taken and evaluated. Radiological tumor assessment by MRI or CT will be performed.

Safety will be evaluated by the incidence of adverse events (AEs), serious adverse events (SAEs), DLTs, and use of concomitant medications.

Anti-tumor activity of MBS8(1V270) will be evaluated via imaging using RECIST and iRECIST criteria, with iRECIST being the leading tumor evaluation criteria.

03

Conditions studied

  • Advanced Solid Tumor
  • Uveal Melanoma, Metastatic
  • Cutaneous Melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Stage I Inclusion Criteria

  1. Male or female aged ≥18 years.
  2. Diagnosis of a or cytologically confirmed solid tumour that was advanced and with progression. No standard treatment existed, or the participant refused standard treatment. Experimental immunotherapy appeared as a feasible exploratory treatment option as per Investigator's assessment.
  3. Tumour lesion(s) accessible to serial .
  4. Was willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and tumour biopsies. Mandatory Baseline and on-treatment tumour biopsies were required. However, a biopsy may have been omitted if the procedure was deemed medically unsafe or not feasible, based on the Investigator's clinical judgment and after discussion with the Medical Monitor (or Sponsor's designee).
  5. according to v1.1. Previously irradiated lesions were measurable if subsequent progression was documented.
  6. (ECOG) performance status 0 to 1.
  7. >3 months as assessed by the Investigator.
  8. Adequate bone marrow, cardiopulmonary, renal and hepatic functions:

    • ≥5.6 mmol/L (≥90 g/dL) (without transfusion or erythropoietin therapy within 4 weeks prior to therapy)
    • Neutrophils ≥1.5×109/L, without growth factor stimulation within 3 weeks prior to the blood test
    • count ≥75×109/L
    • Serum creatinine ≤1.25× or ≥50 mL/min (by formula)
    • Hepatic function: and ALT ≤2.5×ULN; (5×ULN in the case of liver ); ≤1.5×ULN except in the case of Gilbert's syndrome and 2×ULN in the case of liver metastases.
  9. All participants of (defined as \<2 years after last menstruation or not surgically sterile) must have had a negative highly sensitive pregnancy test at Screening (urine/serum) and agreed to use highly effective method for according to the European Union (EU) Clinical Trial Facilitation Group guidance from time of signing the form (ICF) until at least 120 days after the last administration of trial drug. The partners of participants with childbearing potential must have also applied contraceptive methods and were recommended not to donate sperm.
  10. Ability to understand and sign the ICF.

Stage II General Inclusion Criteria The following general inclusion criteria apply to all participants unless cohort criteria specify otherwise.

  1. Male and female aged ≥18 years.
  2. Eastern Cooperative Oncology Group performance status 0 to 1.
  3. Life expectancy ≥3 months as assessed by the Investigator.
  4. Adequate organ function within 7 to 14 days prior to Day 1. • ≥1.5×10⁹/L; platelets ≥100×10⁹/L; haemoglobin ≥9 g/dL (transfusion allowed per site's policy) • Aspartate transaminase/ALT ≤3×ULN (≤5×ULN in case of liver metastases)

    • Total bilirubin ≤1.5×ULN (≤3×ULN in case of Gilbert's syndrome)
    • Creatinine clearance ≥50 mL/min (Cockcroft-Gault or measured)
    • (INR)/activated partial thromboplastin time (APTT) within institutional limits (unless on stable anticoagulation).
  5. Prior systemic anti-cancer therapy with a of ≥14 days plus resolution of drug-related AEs before C1D1. Participants should have recovered from prior therapy-related toxicities to Baseline or Grade ≤1 (except alopecia and other non- AEs) and meet all Baseline laboratory criteria. Any deviation requires documented approval from the Sponsor/Medical Monitor with justification in the source record.
  6. Major surgery ≥4 weeks, palliative radiotherapy ≥2 weeks, stereotactic body radiation therapy to lung/liver ≥3 weeks.
  7. No systemic >10 mg/day prednisone-equivalent within 14 days before C1D1.

    Note: Physiologic/replacement doses (e.g., adrenal insufficiency) up to 10 mg/day prednisone-equivalent, topical, inhaled, intra-articular, intranasal, or ophthalmic steroids are allowed.

  8. All participants of childbearing potential (defined as \<2 years after last menstruation or not surgically sterile) must have a negative highly sensitive pregnancy test at Screening (urine/serum) and agree to use highly effective method for contraception according to the EU Clinical Trial Facilitation Group guidance from the time of signing the ICF until at least 120 days after the last administration of trial drug. The partners of participants with childbearing potential must also apply contraceptive methods and are recommended not to donate sperm.
  9. Ability to provide informed consent and comply with trial procedures.
  10. Lactate dehydrogenase ≤2.0×ULN at Screening (single repeat allowed, if confounded).

Stage II - Cohort A (Cutaneous Melanoma; Pembrolizumab in Combination with MBS8(1V270)) Specific Inclusion Criteria The following inclusion criteria apply specifically to Stage II - Cohort A. 11A. Histologically/cytologically confirmed metastatic cutaneous melanoma. 12A. Prior exposure to pembrolizumab, nivolumab, nivolumab + ipilimumab, or nivolumab + relatlimab with documented SD lasting ≥6 months, or any CR or PR followed by disease progression.

13A. No untreated or unstable . Participants with treated/stable CNS metastasis are eligible if the condition is radiographically stable for ≥4 weeks, no new/worsening neurologic symptoms, and off steroids or on stable/declining ≤10 mg/day prednisone-equivalent for ≥14 days.

14A. Last dose of pembrolizumab, nivolumab, nivolumab + ipilimumab, or nivolumab + relatlimab was given ≤12 weeks prior to Screening, and with no other therapy started.

15A. No prior Grade ≥3 irAE leading to permanent discontinuation of prior anti-PD1/PD L1.

16A. Willing to receive pembrolizumab per SmPC/label-concordant schedule. Stage II - Cohort B (Uveal Melanoma; MBS8(1V270) Monotherapy) Specific Inclusion Criteria The following inclusion criteria apply specifically to Stage II - Cohort B. 11B. Histologically/cytologically confirmed metastatic uveal (ocular) melanoma. 12B. Prior tebentafusp exposure with subsequent progression.

  • With documented SD lasting ≥6 months, or any CR or PR
  • RECIST v1.1 progression on tebentafusp.
  • Washout ≥14 days from the last tebentafusp dose, tebentafusp-related AEs recovered to Grade ≤1/Baseline.
  • No new organ crisis (e.g., hepatic failure risk, spinal cord compromise) in the prior 4 weeks.
  • No escalation of corticosteroids for tumour-related symptoms within 14 days. 13B. Prior exposure to pembrolizumab, nivolumab, or nivolumab + ipilimumab with documented SD lasting ≥6 months, or any CR or PR followed by disease progression, independent of prior tebentafusp therapy.

Exclusion Criteria A participant was not eligible for the trial if any of the following applied. Stage I Exclusion Criteria

  1. Have had biologic, hormonal, anti-neoplastic chemotherapy, or radiation therapy within 4 weeks prior to Screening (6 weeks required for nitrosourea or mitomycin) except for medications with half-lives \<5.5 days.
  2. Metastatic disease that involved major airways or blood vessels or centrally located mediastinal tumour masses of large volume with close relation to the major airways, where tumour necrosis may have caused perforation or severe bleeding episodes. Primary or metastatic intestinal disease in situ where tumour necrosis may have caused gastrointestinal perforation.
  3. Use of agent in the 4 weeks or 5 half-lives prior to the first dose of MBS8(1V270), whichever was shortest.
  4. Major surgical procedure within 14 days prior to the first dose of trial treatment.
  5. Had a history of another primary , except for:

    • Malignancy treated with curative intent and with no known active disease within 2 years prior to the first dose of MBS8(1V270)
    • Adequately treated non-invasive basal skin cancer or squamous cell skin carcinoma
    • Adequately treated uterine cervical cancer Stage 1B or less.
  6. Treatment with systemic medication (including, but not limited to, corticosteroids [>10 mg prednisone per day or equivalent, except topical or inhaled] cyclophosphamide, azathioprine, methotrexate, thalidomide, anti-IL-6 receptor agents, and anti-tumour necrosis factor [TNF]α agents) within 2 weeks prior to initiation of trial treatment, or anticipation of need for systemic immunosuppressive medication during trial treatment.
  7. Treatment with androgen deprivation therapies such as luteinizing hormone-releasing hormone (LHRH) (gonadotropin-releasing hormone [GnRH]) agonists within 2 weeks prior to initiation of trial treatment.
  8. Ongoing irAEs and/or AEs Grade ≥2 not resolved from previous therapies except vitiligo, resolved atopy, limited psoriasis, stable neuropathy Grade 2, hair loss, and stable endocrinopathies with substitutive hormone therapy.
  9. Had uncontrolled intercurrent or chronic illness, but not limited to, ongoing or active infection such as or C, (HIV), immune dysfunction such as disease, psychiatric illness such as depression or suicidal tendency or social situations that would have limited compliance with trial requirements.
  10. Had active or history of immunologic-mediated disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren's syndrome, or Guillain-Barré syndrome.
  11. Had clinically significant cardiac disease, including:

    • Known congestive heart failure Grade III or IV by the New York Heart Failure Association (see Appendix A)
    • Myocardial infarction within 6 months prior to signing the ICF
    • Onset of unstable angina within 6 months prior to signing the ICF.
  12. History of severe allergic episodes.
  13. Known to any component of MBS8(1V270).
  14. Had a history of seizure disorders uncontrolled on medication.
  15. Had a history of clinically significant coagulation or bleeding disorders or abnormalities.
  16. Abnormal or clinically significant coagulation parameters (i.e., INR and APTT) at the discretion of the Investigator.

    Participants treated with anticoagulants were excluded if the coagulation parameters were outside the therapeutic intervals as described in the SmPC for the administered treatment.

  17. Women of childbearing potential who denied remaining abstinent (refrain from heterosexual intercourse) or did not use a highly effective form of contraception that resulted in a failure rate of \<1% per year during the Treatment period and up to 120 days after the last trial drug administration.
  18. Men of who denied following accepted contraception methods during the Treatment and up to 120 days after the last trial drug administration.
  19. Pregnant or lactating women.
  20. Had a history or current evidence of any condition, therapy, or laboratory abnormality that might have confounded the results of the trial, interfered with the participant's participation for the full duration of the trial, made administration of the trial drugs hazardous, or made it difficult to monitor adverse effects such that it was not in the best interest of the participant to participate, and in the opinion of the treating Investigator.
  21. Had an autoimmune disorder requiring immune-modulating treatment (>10 mg prednisone per day or equivalent, except topical or inhaled) during the last 2 years prior to the first dose of MBS8(1V270).

Stage II General Exclusion Criteria The following general exclusion criteria apply to all participants unless cohort criteria specify otherwise.

  1. Uncontrolled intercurrent illness: active infection requiring IV therapy, uncontrolled congestive heart failure, unstable angina, significant arrhythmia, recent myocardial infarction (≤6 months), or uncontrolled hypertension.
  2. Known active HIV with uncontrolled viraemia, active hepatitis B virus (HBV)/ virus (HCV) with high viral load (HBV >20,000 IU/mL and HCV >800,000 IU/mL) despite therapy (enrol per local guidelines, if controlled).
  3. Pregnant or breastfeeding.
  4. Second malignancy requiring active therapy (except adequately treated non-melanoma skin cancers, in situ cancers, or malignancies in remission ≥2 years)
  5. Allergy/hypersensitivity to trial drug components.
  6. within 28 days prior to C1D1.
  7. >500 ms.
  8. Any condition that, in the Investigator's judgement, compromises safety or compliance.
  9. Active autoimmune disease requiring systemic treatment in the past 2 years (topicals/inhaled/physiologic replacement allowed).
  10. Any prior exposure to systemic or IT immunotherapy (except tebentafusp, pembrolizumab, nivolumab, ipilimumab, and relatlimab), but including Montanide, TLR7, TLR8, and TLR9 agonists, polyinosinic:polycytidylic acid, cationic adjuvant formulation, messenger ribonucleic acid -based vaccines, T cell therapy, and oncolytic viruses.
  11. Participants who have been previously treated with experimental anti-cancer vaccines.

Stage II - Cohort A (Cutaneous Melanoma; Pembrolizumab in Combination with MBS8(1V270)) Specific Exclusion Criteria The following exclusion criteria apply specifically to Stage II - Cohort A. 12A. Prior life-threatening or Grade ≥3 immune-related toxicity to requiring permanent discontinuation of these therapies (exception: controlled endocrinopathies on replacement).

13A. Interstitial lung disease/pneumonitis (current or history requiring steroids).

14A. Concurrent anti-cancer therapy other than trial-allowed supportive care. 15A. Histologically/cytologically confirmed cutaneous acral melanoma and mucosal melanoma.

Stage II - Cohort B (Uveal Melanoma, MBS8(1V270) Monotherapy) Specific Exclusion Criteria The following exclusion criteria apply specifically to Stage II - Cohort B. 12B. Active, uncontrolled hepatic dysfunction not attributable to tumour (e.g., acute hepatitis).

13B. Any specific to MBS8(1V270) per IB (e.g., known hypersensitivity to , cohort-specific risk factors).

14B. Brain metastases.

Terms in these criteria, in plain language(37)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (estimated)

Study arms

  • Experimental
    MBS8(1V270)

    Monotherapy arm

    Drug: MBS8(1V270)

  • Experimental
    MBS8 (1V270) + pembrolizumab

    MBS8 (1V270) + pembrolizumab combination arm

    Drug: MBS8(1V270) and pembrolizumab combination

Interventions

  • DrugMBS8(1V270)

    MBS8(1V270) monotherapy

  • DrugMBS8(1V270) and pembrolizumab combination

    Drug page: PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    MBS8(1V270) and pembrolizumab combination

06

What researchers measure

Primary outcomes

  1. Adverse events

    Type and number of adverse events

    Time frame: 42 days

  2. Dose limiting toxicities

    Dose limiting toxicities (DLTs) and the MTD for determination of RP2D of MBS8(1V270). Stage I only

    Time frame: 23 days

  3. Safety related biomarkers

    Plasma levels of safety related cytokines IL-6 and TNF-alpha wil be assessed

    Time frame: 23 days

Secondary outcomes

  1. Best overall response

    Complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), unconfirmed (iUPD) and confirmed PD (iCPD), assessed according to Response Evaluation Criteria in Solid Tumours (RECIST) and immune RECIST (iRECIST

    Time frame: 42 days

  2. Pharmacokinetic profile of drug substance

    The plasma concentration time profile of MBS8(1V270) will be assessed

    Time frame: 22 days

07

Study locations

5 of 5 sites recruiting
  • Herlev and Gentofte Hospital, Center for Cancer Research
    Herlev, DK-2730, Denmark
    Recruiting
    • Rikke Eefsen, MD · Contact
  • Institut Catalá de Oncologia - Hospital Duran i Reynals.
    Barcelona, Spain
    Recruiting
    • José M Piulats Rodríguez, MD, PhD · Contact
  • Fundacion Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (FJD)
    Madrid, 28015, Spain
    Recruiting
    • Victor Moreno, MD PhD · Contact
  • Centro Integral Oncológico Clara Campal (CIOCC)
    Madrid, 28050, Spain
    Recruiting
    • Emiliano Calvo, MD PhD · Contact
  • Consorcio Hospital General Universitario de Valencia
    Valencia, Spain
    Recruiting
    • Alfonso Berrocal, MD. PhD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Mar 2027, 71 months after the start.

Of 32 phase 1 interventional studies under Uveal Melanoma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 66. This study's planned 71 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2021
First posted
Apr 22, 2021
StartActual
Apr 12, 2021
Primary completionEst.
Mar 2027
CompletionEst.
Jun 2027
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04855435
Lead sponsor
MonTa Biosciences ApS
Responsible party
Sponsor
First posted
Apr 22, 2021
Start date
Apr 12, 2021
Primary completion
Mar 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Aug 10, 2026

Study contacts

Simon S Jensen, PhD
Contact
simonjensen@montabiosciences.com
+45 5118 6306
Steven Glazer, MD
Contact
stevenglazer@montabiosciences.com
+45 25674434
Kristoffer S Rohrberg, MD PhD
principal investigator · University Hospital of Denmark, Department of Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion